Breaking Finance News

B. Riley disclosed Ekso Bionics Holdings (OTC:EKSO), boosting its stock price target to $8.00 earlier today

Yesterday Ekso Bionics Holdings (OTC:EKSO) traded 1.58% lower at $3.83. EKSO’s 50-day average is $4.47 and its two hundred day moving average is $5.59. With the last stock close down 33.11% relative to the two hundred day average, compared with the Standard & Poor’s 500 Index which has fallen -0.01% over the same time. 64,893 shares of the stock traded hands, down from ann average volume of 188,838.

B. Riley raised the target stock price of Ekso Bionics Holdings (OTC:EKSO) to $8, stating a possible upside of 1.09%,

See Graph Below:

Ekso Bionics Holdings (OTC:EKSO)

Ekso Bionics Holdings has a one-year low of $3.64 and a 52 week high of $10.08 and has a market cap of $0.0.

Brief Synopsis On Ekso Bionics Holdings (OTC:EKSO)

Ekso Bionics Holdings, Inc. designs, develops, and sells exoskeletons for use in the healthcare, industrial, military, and consumer markets in North America, Europe, the Middle East, and Asia. The company operates through Engineering Services and Medical segments. It primarily offers Ekso GT, a bionic suit that provides the ability to stand and walk over ground with a reciprocal gait using a cane, crutches, or a walker to individuals with spinal cord injuries, stroke, and other lower limb paralysis or weakness. The companyÂ’s Ekso device is primarily used in a clinic or rehabilitation setting. It also performs research and development work on human exoskeletons and related technologies. The company has a collaborative partnership with Lockheed Martin Corporation to develop products for military applications, as well as a license agreement with OttoBock Healthcare Products Gmbh. Ekso Bionics Holdings, Inc. was founded in 2005 and is headquartered in Richmond, California. Ekso Bionics Holdings, Inc. operates as a subsidiary of Magee Rehabilitation Hospital, and PA.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *